Clinical trial for the evaluation of the efficacy and safety of HP-01 on blood flow improvement

12 weeks, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HP-01 on blood flow improvement

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004455

Enrollment

Registered

2019-11-21

Start date

2019-11-08

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects will be randomized tot the test group or control group. Subjects will orally self-adminster test food or placebo three times a day, 2 dose per one time for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The subjects who agrees to participate in this study before the start of the study and who has signed the informed consent form 2) The subjects whose age over 25 and over, 70 and less 3) The subjects who satisfy three or more items under the following conditions: A. The subjects with a fasting total cholesterol of 200 to 239mg/dl B. The subjects with a fasting LDL-cholesterol of 130 to 159mg/dl C. The subjects with a fasting blood sugar of 100 to 125mg/dl D. The subjects with a systolic blood pressure of 120 to 139mmHg E. The subjects with a BMI(Body mass index) of over 25 kg/? and less than 30 kg/? F. The subjects with a Waist to hip ratio of over than 0.9 male and 0.85 female

Exclusion criteria

Exclusion criteria: 1) The patients with uncontrolled hypertension(systolic blood pressure over 160mmHg or diastolic blood pressure over than 100mmHg, after 10 minutes of stabilization) 2) The patients with uncontrolled diabetes mellitus(fasting blood sugar over than 180mg/dl) 3) The subjects, who is deemed unfit for this human an application test by the investigator

Design outcomes

Primary

Measure	Time frame
Platelet aggregability;Treatment emergent adverse events	—

Countries

Korea, Republic of

Contacts

Public ContactSoo Wan Chae

Chonbuk National University Hospital

swchae@jbctc.org+82-63-259-3049

Outcome results